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1. INTRODUCTION 
The rapid development of technology and progress in the medical sciences have resulted in 
an amazing extension of life expectancy at the time of birth, so an aging population has presented 
the healthcare system with new challenges. Two main urogynaecological symptoms, such as stress 
urinary incontinence (SUI) and pelvic organ prolapse (POP), have been prevalent lately, and the 
cumulative risk of surgery for POP or SUI by the age of 80 years has been estimated at 11.1% [1].   
1.1. Complications of urogynaecological operations 
The potential complications of using transvaginal mesh are wide-ranging, from mild to 
seriously life-threatening. The most common complications, as reported in the US Food and Drug 
Administration (FDA) Public Health Notification, include mesh erosion at the site of vaginal 
incision, lower urinary tract infection, pelvic pain, dysuria, recurrence of prolapse or 
incontinence, de novo UUI, de novo SUI dyspareunia, and perforation of the bowel, and/or 
vessels during mesh insertion [2,3].  
 
1. AIMS OF THE THESIS 
 The aims of our series were to ascertain the feasibility of vaginal prosthesis operations 
following the FDA warnings.  
 We examined an “oldy but goody” method for the of some of the most serious mesh-related 
complications, including VVF. 
 We investigated the long-term utility of a newly developed anterior vaginal mesh method 
for the correction of POP–Q Stage 2–4 anterior vaginal prolapse. 
 We designed a prospective randomized study for evaluating the effectiveness of an 
alternative operative method for reconstructing POP–Q 2–3 concomitant with genuine SUI. 
 
2. HYPOTHESIS  
Several incongruities can be found in the available literature on the effectiveness and side-
effects of vaginal prosthesis operations. Therefore, a retrospective study was organized to ascertain 
the feasibility of vaginal prosthesis operations in our practice following the FDA warnings. We 
hypothesised that the long-term success rates for TVM operations on POP and SUI reconstruction 
with an acceptable frequency of side-effects are better than those found in the literature. 
Vesicovaginal fistula (VVF) formation is an extremely rare but embarrassing complication 
of mesh methods [4,5]. A prospective short series study was organized to evaluate the utility of the 
Lehoczky’s island flap [6] method in reconstructing the mesh-related bladder perforation and VVF. 
We assumed that the Lehoczky’s island flap method is highly effective in reconstructing prosthesis-
formed fistulas.  
Mesh extrusions, dyspareunia or vaginal discharges are more frequent issues after vaginal 
prosthesis operations. Reviewing the literature, we have provided good evidence that the folding 
and contraction of the implanted meshes may cause pain, dyspareunia and the extrusion of the 
implants [7,8,]. For this purpose, a new concept involving an anchorless implant was developed. 
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We have hypothesised that our new anchoring technique and non-folding meshes result in better 
long-term results than other vaginal prosthesis methods.  
The anti-SUI efficacy of the prosthetic placement is barely 72–83% [9-11]. Our previous 
study, where the anterior arms of the TVM were anchored by two stitches, resulted in greater anti-
SUI efficacy (90%). We hypothesise that the original TVM operation may be followed by residual 
SUI since the strengthening of the back arms may result in a backward dislocation of the entire 
mesh.    
 
3. MATERIALS AND METHODS 
3.1. The experimental protocol in Study 1  
In Study 1 we evaluated and compared the anti-POP effect, anti-stress incontinence (anti-
SUI) efficacy, and the early (six weeks) and late (36 months) postoperative complication rates for 
the anterior vaginoplasty and the transvaginal mesh (TVM) operations.  
3.1.1. Material and methods 
The retrospective cohort study comprised 120 women who presented for the correction of 
SUI in conjunction with symptomatic anterior compartment POP–Q 2–3 at the Departments of 
Urology and Obstetrics and Gynaecology at the University of Szeged, Hungary, between January 
2013 and January 2014. Sixty patients had undergone Kelly–Stoeckel vaginoplasty and the other 
60 cases had had TVM surgery. Both study groups were homogenized as much as possible 
according to age, parity, body mass index (BMI) and menopausal status. The symptomatic POP–
Q Stage 2–3 anterior prolapse is defined as the maximum extent of the prolapsed anterior vaginal 
wall being within 1 cm above and 6 cm below the hymen [12,13]. Coexisting symptomatic SUI 
was determined with pad or cough tests.  
3.1.2. Exclusion criteria 
The exclusion criteria were as follows: a history of mesh use or anti-incontinence pelvic 
procedures, antidepressant therapy, pregnancy and cancer of the pelvic organs. 
3.1.3. Efficacy criteria 
The efficacy of the POP repair was taken as a significant (>1 cm) improvement at points 
Aa, Ba and C and total vaginal length (TVL) according to the POP–Q system (International 
Continence Society) during the follow-up [12,13]. Anti-incontinence efficacy was classified as no 
further SUI diagnosed by cough or pad test. 
Early surgical complications were classified using the Clavien–Dindo (CD) classification 
system [14]. As concerns the long-term postoperative complications of the sling and mesh 
procedures, we determined the rejection rate, the presence of DNUS or urinary tract infection (UTI) 
and the need for reoperation.  
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3.1.4. The operative method used 
All prosthesis operations were carried out with 100% polypropylene monofilament 
permanent meshes produced by Aspide® SURGIMESH® PROLAPSE (Aspide Médical, La 
Talaudière, France). The implanted vaginal prosthesis has pores which are 1.6 x 1.7 mm in size 
and is approved for anterior vaginal repair.  
Traditional anterior colporrhaphy was augmented with Kelly’s plication [15] in order to 
thicken the cervicopubic fascia which promotes the appropriate elevation of the bladder neck and 
closure of the urethra, enhancing the anti-incontinence effect.  
3.1.5. Statistical analyses 
The SPSS 17.0 program package was used to analyse the data. The non-parametric design 
of the continuous variables was verified with the Shapiro–Wilk test. Categorical and continuous 
variables were compared with the χ2 test and Kruskal–Wallis test, respectively.  
 
3.2. The experimental protocol in Study 2  
A prospective short series study was organized to evaluate the utility of the Lehoczky’s 
island flap method for reconstructing the mesh-related bladder perforation. 
3.2.1. Material and methods 
Women (mean age 62, n=3) with clear stress urinary incontinence underwent a TOT 
procedure using monofilament polypropylene tapes (Surgimesh sling 45x1cm VS112-KY, Aspide 
Médical, La Talaudière, France) at different hospitals who had urine leakage postoperatively and 
the  postoperative examinations verified  vesico-vaginal fistulas. 
The flap closing method was effective if the patients involved at the three-month final 
follow-up self-reported no urine leakage and if all of them were free of fistulas, without any 
complaint of dyspareunia. 
3.2.2. The operative method used 
The vagina was exposed with a deep episiotomy, and the vaginal part of the fistula and the 
wide inflamed area were then excised.  The opening of the fistula in the bladder was closed with 
absorbable interrupted sutures. The vaginal wall defects were covered with Lehoczky’s skin 
flaps. The oval-shaped fatty-skin flaps were dissected from the area of the genitofemoral sulcus 
in all cases with a diameter of 3–4 cm on the same side as the fistula was located. The island flap 
was pulled into the vagina through a tunnel under the bulbocavernous muscle. The fatty part of 
the flap was situated between the vagina and the bladder, while the skin covered the vaginal 
defect as a patch and its edges were sutured to the wall of the vagina. The donor site of the flap 
was closed with interrupted sutures. The final follow-up was three months, when a cystoscopy 
and a bimanual examination were performed.  
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3.3. The experimental protocol in Study 3 
The available international literature provides good evidence that the anchoring 
techniques used in the placement of vaginal implants are a major factor in the occurrence of 
complications: organ perforation involved in the anchoring technique, unbalanced scar formation 
at the anchoring points, tension, folding and contraction that can cause pain and/or dyspareunia 
[33, 34]. For this purpose, a new concept involving an anchorless implant was developed. The 
assumption was that an anchorless neo-pubocervical fascia would accurately mimic the 
physiological support system, therefore providing adequate support. 
3.3.1. Materials and methods 
A prospective, multi-centre, international study was organized to evaluate the feasibility, 
safety and cure rate for POP surgery using the SRS implant. The patients involved (n=20) with at 
least POP–Q Stage 2 anterior compartment prolapse were recruited from the gynaecological 
clinics in each participating hospital (Ma’ayanei HaYeshua Hospital, Bnei Brak, Israel; Catholic 
University Gemelli Hospital, Rome, Italy; University of Szeged, Szeged, Hungary).  
Exclusion criteria included: previous POP repair with mesh, age > 75 years, old POP–Q 
less than Stage 2 or asymptomatic POP. 
Objective anatomical success was defined as POP–Q Stage 0 and 1 prolapse using the 
NIH criteria [40]. The Pelvic floor disability index (PFDI-20) is divided into three domains: 
Pelvic Organ Prolapse Distress Inventory 6 (POPDI-6), Colorectal Anal Distress (CRAD-8) and 
Urinary Distress Inventory (UDI-8). Patients were followed at two weeks and two, six, twelve 
and 24 months after surgery. Objective and subjective primary end points were defined at 24 
months. 
3.3.2. The invented device 
The device is composed of an ultra-light titanized polypropylene mesh (16 g/m2) stretched 
and held in place by a U-shaped flexible frame made of a biocompatible implantable polymer 
(Figure 9). The SRS lateral arms have been designed to mimic the shape of the ATFP. The frame 
is composed of a solid but flexible material.  
3.3.3. The surgical technique 
The surgical technique involves performing an incision on the anterior vaginal wall and a 
central dissection of the bladder from the vagina. Dissection is then extended to the para-vesical 
space for direct bilateral palpation of the ischial spines. The implant is positioned in place with no 
tension, with the arms not flexed and the mesh fully stretched. The device is inserted between the 
bladder and the vaginal mucosa with the lateral arms following the anatomy of the ATFP. The 
connecting bridge is positioned under the pubic symphysis. No other anchoring techniques are 
used. The vaginal incision is closed with no tension.   
3.3.4. Statistical analysis 
Statistical analysis involved the Analysis of Variance (ANOVA) test, where the null 
hypothesis is that all subgroup means are equal. The results from the two-way ANOVA on 
changes in points Aa, Ba and C by subject and visit were analysed, looking at the p-values of the 
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term visit in the model to evaluate statistical significance. Pre- and post-surgery POP–Q 
measurements were calculated using a non-parametric Wilcoxon signed ranks test. 
 
3.4. The experimental protocol in Study 4 
 Although the rate for concomitant SUI in patients with POP is as high as 63–80% [16], 
the effective treatment for coexisting SUI and POP is still debated. The anti-SUI efficacy of the 
prosthetic placement is barely 72–83% [34-36]; however, it is assumed that a combination of a 
synthetic mesh with the sling operation [26,27,41] will substantially increase the cure rate for 
concomitant SUI. 
Therefore, the research group developed a modification to the transobturator four-arm TVM to 
increase its anti-incontinence effect. In the original TVM, the posterior part of the mesh is 
anchored to the anterior aspect of the cervix and the anterior arms are spread under the bladder 
neck with stabilizing sutures. We hypothesise that the original TVM operation can be followed 
by residual SUI since the strengthening of the back arms may result in a backward dislocation of 
the entire mesh. The posterior movement of the mesh allows the dorsal rotation of the urethra 
since the mid-urethra is not suspended. The proposed modification to the original surgical 
procedure includes the suture of the anterior part of the mesh to the mid-urethra to prevent the 
mesh sliding.  
3.4.1. Material and methods 
We designed a single-centre, prospective, double-blind (participant, investigator/surgeon, 
outcome assessor), randomized, controlled trial to evaluate the anti-SUI success rate for the 
modified TVM. The study is being conducted in accordance with the Declaration of Helsinki and 
has been approved by the local medical ethics committee at the University of Szeged under 
reference number 55/2016. 
Patients will be recruited from the urogynaecology consultation at the Division of 
Urogynaecology, Department of Obstetrics and Gynaecology, University of Szeged, Hungary. All 
study participants will be provided an information sheet and a consent form describing the study 
in brief, so they can decide whether to participate in the study. This longitudinal study involving 
patients all successively scheduled for surgery for symptomatic prolapse POP–Q Grade 2 or 3 and 
coexisting SUI. The study will be conducted for an estimated maximum of 18 months.  
The symptomatic POP–Q Stage 2–3 (determined by the gynaecological examination using 
the International Continence Society quantification system) [18] anterior vaginal wall prolapse is 
defined as the maximum extent of the prolapsed anterior and middle compartments being within 
1 cm above and 6 cm below the hymen [20,38].  
In all cases, SUI will be visualized after a complete physical examination is performed 
(confirmed by pad test/Bonney test/two dimensional (2-D) introital sonography and urodynamic 
examination).  
 
 
7 
 
3.4.2. Inclusion criteria 
Female adults aged over 40 with coexisting pelvic floor defects will be recruited, at least 
one year following delivery, irrespective of parity and pre- or postmenopausal state, medically 
and physically fit for the measurement and therapeutic surgeries, and, in the case of systemic or 
local oestrogen treatment, stable for the past three months prior to inclusion. The patients will be 
randomized to one of the study groups using a computer-generated list. 
3.4.3. Exclusion criteria 
Exclusion criteria are urge; mixed incontinence; prolapse < Grade 2 or > Grade 3 POP–Q; 
apical or posterior compartment prolapse; dysuria (bladder tumour and/or  neurogenic urinary 
bladder damage); a history of mesh use or anti-incontinence pelvic procedures; pregnancy (urine 
test); lactation period not yet finished; current urinary tract or vaginal infection; menstruation on 
the day of examination; contraindications for measurements or interventions, for example, acute 
inflammatory or infectious disease, tumour or fracture; de novo systemic or local oestrogen 
treatment (<3 months); de novo drug treatment with anticholinergics or other active substances 
for bladder-related disorders (tricyclic antidepressants and selective serotonin reuptake 
inhibitors); and cancer of the pelvic organs. 
3.4.4. Operative method  
 All operations will be carried out using 100% polypropylene monofilament meshes 
produced by Aspide® SURGIMESH® PROLAPSE (Aspide Médical, La Talaudière, France). 
The anterior vaginal wall will be incised longitudinally throughout its thickness from the 1.5 cm 
below the urethral meatus (where the mid-urethra is located) to the cervix. The thickness of the 
dissection, the location of the vaginal incision, the placement of the mesh and the closure of the 
incision will vary only minimally, and the length of the incision is intended to be 6–7 cm. All the 
operations will be performed by two experienced senior surgeons who are subspecialists in 
urogynaecology. The posterior part of the mesh will be anchored to the anterior side of the cervix 
using two Prolene® 2-0 sutures (Ethicon, Issy-les-Moulineaux, France). 
The mesh will then be spread by securing its anterior parts beneath the mid-urethra using 
two Vicryl 2-0® absorbable sutures (Ethicon, Issy-les-Moulineaux, France)  
A urinary catheter will be removed on the morning of the postoperative day. A vaginal 
gauze pack (gauze soaked in Betadine iodine) will be placed for 12h.  
3.4.5. Efficacy criteria 
The follow-up period of the study will be 36 months. The primary outcome measures will 
be a significant improvement in POP repair and objective cure of SUI following surgery. The 
efficacy of POP repair will be understood as a significant (>3 cm) improvement during follow-up 
at points Aa, Ba, C and D using the POP–Q system (International Continence Society) [20,38]. 
Anti-incontinence efficacy is classified as no further SUI, as diagnosed by cough tests and 
urodynamic examinations. The secondary measurement outcome will comprise the intraoperative 
findings and postoperative factors. As concerns the long-term postoperative complications of the 
mesh procedures, we will determine the extrusion rate, the presence of DNUS or UTI, and the 
need for reoperation.  
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The subjective cure for prolapse and incontinence will be measured with a significant 
enhancement of the Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ-12) 
and PFDI-20 scores. The PISQ-12 and PFDI-20 have been validated to assess the impact of SUI 
symptoms on quality of life and sexuality and relate well to the prolapse symptoms. 
3.4.6. Data collection 
Baseline (before the intervention phase) and follow-up measurements (of primary, 
secondary and tertiary outcomes) after six weeks to three years will be performed at the Division 
of Urogynaecology, Department of Obstetrics and Gynaecology, University of Szeged, Hungary, 
by experienced urogynaecologists, who will be blinded to group allocation of participants and 
who will not operate on the patients  
3.4.7. Statistical analyses 
All statistical analyses will be conducted using SPSS software version 22 (IBM, Armonk, 
NY, USA). All tests will be two-sided, and significance will be set at p<0.05. Efficacy 
measurements will be adjusted by intention-to-treat analysis. Missing values will be replaced 
using the last observation carried forward (LOCF) method. No subgroup analyses are planned. 
Standard deviations, 95% confidence intervals and median will be used for the descriptive 
analyses. Regarding the primary and secondary outcome analysis, the Chi-square test or Fisher’s 
exact test will be employed to identify any objective outcome differences among groups. 
 
4.  RESULTS  
4.1. Comparison of the effectiveness of vaginal prosthesis and colporrhaphy operations  
 
The main results of our study were the following. The TVM significantly improved the prolapse 
status (POP–Q of Aa (p<0.001), Ba (p<0.001) and C (p<0.001)) compared to that of anterior 
colporrhaphy, while the total vaginal length was significantly shortened (p<0.001)  
The recurrence of anterior compartment POP (36.5%, p<0.001) and SUI (45%, p<0.001) or 
reoperation due to recurrence of SUI (8.3%, p=0.007) and POP (26.7%, p<0.001) during the 36-
month follow-up period was typical of the anterior colporrhaphy patients. Prolapse repair was 
achieved in a significantly higher proportion of the patients who underwent TVM compared to 
their anterior colporrhaphy counterparts (91.7% vs 63.3%, p<0.001). Urinary tract infection was 
not more prevalent after the prosthesis operations than after anterior colporrhaphy. DNUS was 
found not significantly more often in the prosthesis than in the colporrhaphy group (p=0.006). The 
extrusion rate was 8.33% in the TVM group. The overall reoperation rate was remarkably lower in 
the TVM group than in the colporrhaphy group (16.7% vs. 35%).  
The operation took longer in the TVM group as compared with the anterior colporrhaphy 
(p=0.02). The estimated blood loss (83.1ml vs 75.3ml) during the operation and the number of 
early reoperations were approximately the same in both groups (p=0.71, p=0.31 and p=0.75). The 
occurrence of bladder injury and the need for immediate postoperative blood transfusion were 
negligible in both the study groups.  
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Total complication rates of 33.3% in the TVM group and 25% in the colporrhaphy group 
were noted with non-significant differences (p=0.4). CD 1 complications predominantly occurred 
in the group of women operated on with prostheses, while anterior colporrhaphy operations were 
followed mostly by CD 2 . 
 
4.2. Effectiveness of Lehoczky’s island flap method in reconstructing the mesh-related 
bladder perforation 
Among the operated patients at the third week of follow-up, no vesicovaginal fistulas were 
found by cystoscopy, and bimanual examinations demonstrated that Lehoczky’s island flap healed 
per primam in our short-term series involving Lehoczky’s island flap. 
At the three-month final follow-up, patients self-reported no urine leakage, and all of them 
were free of fistulas and dyspareunia. 
4.3. Feasibility of the Self-Retaining Support Implant in the POP–Q Stage 2–4 reconstruction 
 Twenty women were recruited for the SRS study. The mean age of the patients enrolled 
was 61.9 years, and the mean number for previous parity was four. The participants were slightly 
overweight (BMI: 28.13), and the vast majority of them had no anamnestic hysterectomy or 
prolapse surgery.  Preoperative mean POP–Q measurements were Aa=1.40 (-1 to 3) cm, Ba=2.3 
(-1 to 6) cm and C=0.4 (-7 to 6) cm. Nineteen (95%) patients suffered from both an anterior and 
an apical compartment prolapse, while one (5%) patient only had an anterior prolapse.  
The anatomical outcome at the two-year follow-up. Seventeen (84.2%) patients had a Stage 
0 prolapse, and three patients (15.8%) had a Stage 1 prolapse. At the 24-month follow-up, 
significant anatomical changes were found at points Aa (1.4 to -2.9cm), Ba (2.3 to -2.8cm) and C 
(0.4 to -7cm). No cases of mesh erosion or chronic pelvic pain were documented at follow-up . 
Surgical time for the SRS implantation averaged 31.2 (21–50) min. Estimated total surgical blood 
loss averaged 205 (150–500) ml. Estimated blood loss for patients who underwent the implant-
only procedure averaged 165 ml. No intra-operative complications were observed. 
As for the subjective outcome, PFDI-20 scores showed significant improvement of both 
prolapse and urinary domains as well as improvement in total scores. No deterioration was noted 
in the colorectal or the incontinence domains of the questionnaire.  
Considering a standard MID of 15 points per domain and 45 points in total PFDI scores, 
results showed a significant improvement in the prolapse domain, incontinence domain and total 
PFDI-20 scores. Pelvic Organ Prolapse Distress Inventory 6 (POPDI-6) (POP domain) showed a 
decrease of 41.94 points (p<0.0001) at follow-up from baseline scores. The Colorectal-Anal 
Distress Inventory 8 (CRADI-8, posterior compartment domain) scores were 14.5 points 
(p=0.0016) lower at follow-up than baseline and demonstrated no deterioration at the posterior 
pelvic compartment. Urinary Distress Inventory 6 (UDI-6, urinary incontinence domain) showed 
a decrease of 36.3 points (p=0.0167). The total PFDI score was decreased by 92.75 points 
(p=0.0001). 
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Postoperatively, one patient received one unit of packed cells and no events of urinary 
retention were recorded. One patient developed de novo stress urinary incontinence, which was 
treated successfully with pelvic floor muscle training. One case (5%) of frame erosion into the 
anterior vaginal wall was documented eight months following the procedure. The eroded part of 
the frame was resected under local anaesthesia in an ambulatory setting. The patient’s symptoms 
were relieved immediately after the resection. This was the only case where a large frame was used, 
which we hypothesise to have caused excessive pressure on the vaginal mucosa, causing the 
erosion. 
 
5.  CONCLUSION 
1. We found that the TVM operation is a highly effective method for the reconstruction of 
POP (91.3%) and a significantly higher proportion of the patients who underwent TVM 
experienced remarkable improvement in the POP–Q system compared to anterior 
colporrhaphy. Surprisingly, an extremely high success rate for SUI reconstruction (90%) 
was observed among patients who underwent mesh surgery.  
2. The overall reoperation rate, including the extrusion rate, was remarkably lower in the 
prosthesis group than in the colporrhaphy group (16.7% vs 35%).  
3. An ongoing prospective randomized double-blind study was designed to better evaluate the 
anti-incontinence effect of the original TVM method. We believe that the modification of 
the original TVM method with two suburethral anchoring sutures will lead to further 
improvement in the anti-SUI effect of mesh operations, a fact which is also examined in 
our prospective study.  
4. The rate for bladder perforation rate and consecutive vesicovaginal fistulas after mesh 
surgery is low, but the successful reconstruction of VVFs poses challenges for surgeons. 
The use of Lehoczky’s island ﬂap may be a good option for the repair of large vaginal 
defects caused by implants.  
5. The most common serious complication of prosthesis operations is mesh extrusion at a rate 
of 10.3%. Current operative techniques do not assure that the mesh is placed in a flat, non-
folded, tension-free fashion, thus potentially leading to the extrusion of the implant. The 
SRS solid frame precludes mesh contraction and bunching and seems to have significantly 
better postoperative results with no mesh erosion, dyspareunia or UTI.  
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